SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...

Invesco S&P 500 Pure Value ETF offers low valuations, but underperforms peers due to high volatility and expenses. Read what ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

A young local startup offering virtual appointments for patients at risk for dementia and cognitive decline is getting ready ...

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...

Medicare Advantage (MA) insurers Alignment Healthcare and Clover Health both reported increased membership growth ahead of ...

Five former lobbyists have been appointed or nominated to President-elect Trump’s Cabinet, signaling he may not be as closed ...

Self-funded Pennsylvania-based health plan Imagine360 is buying Ardent Health’s third-party administrator (TPA) HealthFirst, ...